Positive Health Online
Your Country
![[Image: http://www.abundanceandhealth.co.uk]](/img/original/BannerAvatar/2836.df7d2315253110ff5b3a566f94871f99.jpg "http://www.abundanceandhealth.co.uk")
![[Image: http://www.balens.co.uk]](/img/original/BannerAvatar/2148.50367fa908013fae0a7f1a171543ef92.jpg "http://www.balens.co.uk")
![[Image: https://www.water-for-health.co.uk/]](/img/original/BannerAvatar/4046.12831f50177f8848ee87b8e94411d6b3.jpg "https://www.water-for-health.co.uk/")
![[Image: http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer]](/img/original/BannerAvatar/1859.1296090fd8385e7ceff51c8011559097.jpg "http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer")
Research: THELEN and colleagues,
Listed in Issue 113
Abstract
THELEN and colleagues, Department of Urology, Institute of Human Genetics, Georg-August-University, Gottingen, Germany, have researched the inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Background
Telomerase activity is an important factor in cellular immortality and carcinogenesis. The aim of this study was to determine the potential of silibinin as an anticancer drug that down-regulates telomerase activity and prostate specific antigen (PSA).
Methodology
Prostate cancer cells in culture were treated with silibinin, and various biochemical assays were performed.
Results
Silibinin inhibited the expression and secretion of prostate specific antigen. The concentrations of the enzyme telomerase and its activity decreased significantly in the presence of silibinin.
Conclusion
The measured effects underline the possible therapeutic use of silibinin as a medication for prostate cancer.
References
Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. Journal of Urology 171 (5): 1934-1938, May 2004.
